Coverage: The Meridian legal market record (editorial).
MENA-region scope only; no African country is named in the release or the syndicated copy reviewed.
| Record ID | TX-AFR-2025-0015 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Patent licence, In-licensing, Trade mark licence |
| IP rights | patent, regulatory data, trade mark |
| Status | Signed |
| Qualifying date | 2025-12-03 |
| Sector | Life sciences · Pharmaceuticals – cardiometabolic |
| African markets | Multi-jurisdictional |
| Licensed territory | MENA region. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, single · 1 source(s) |
| Last verified | 2026-10-25 |
Parties
- Althera Laboratories Limited (Ireland): licensor
- Tabuk Pharmaceuticals (Saudi Arabia): licensee
Key terms
- Interest: licence; Exclusivity: not stated by source; Territorial scope: MENA region
Sources
- Althera Laboratories and Tabuk Pharmaceuticals Announce Strategic Partnership for Advanced T2D Therapy in MENA, Althera Laboratories / Tabuk Pharmaceuticals (via EIN Presswire, carried by National Law Review), 2025-12-03
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.


